Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Guardant Health (GH)
NASDAQ:GH
Guardant Health (GH) Stock Price & Analysis
1,764 Followers
GH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.81 - $41.06
Previous Close$30.75
Volume957.24K
Average Volume (3M)2.08M
Market Cap
$3.76B
Enterprise Value$5.08B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$1.32B
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Aug 01, 2024EPS Estimate
-$0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.92
Shares Outstanding122,369,214
10 Day Avg. Volume1,838,526
30 Day Avg. Volume2,082,093
Standard Deviation0.17
R-Squared0.13
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)63.79
Price to Sales (P/S)23.33
Price to Cash Flow (P/CF)-29.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.42
Enterprise Value/Gross Profit15.09
Enterprise Value/Ebitda-9.64
Forecast
1Y Price Target
$38.15Price Target Upside24.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Guardant Health News
PremiumCompany Announcements
Guardant Health Appoints Oncology Expert to Board of Directors
Bulls Say, Bears Say
Bulls Say
Coverage And PricingGH management has demonstrated their ability to achieve ADLT status and negotiate favorable pricing, giving more confidence in Shield's average selling prices.
FDA ApprovalThe FDA Advisory Committee voted that the benefits of Shield in CRC detection outweigh the risks, paving the way for likely first line FDA approval.
Market OpportunityBlood-based CRC screening tests are much easier to administer relative to colonoscopy or stool-based screening methods, potentially increasing market penetration.
Bears Say
FDA ConcernsFDA is seeking mitigation strategies to address the lower AA performance and inform the physicians and patients accordingly.
Financial ImpactWith the PCP sales force expected to be a significant source of cash burn for GH, investors will be focused on what the AdCom portends for Shield’s LT opportunity and if the cash burn is warranted.
Product PerformanceShield's AA sensitivity of 13% is meaningfully lower than that of Cologuard (42%), FIT (about 24%) and Epi proColon (about 22%).
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was $15.81 and its highest was $41.06 in the past 12 months.
What is Guardant Health’s market cap?
Currently, no data Available
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is Aug 01, 2024 which is in 11 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on May 09, 2024. The company reported -$0.94 earnings per share for the quarter, missing the consensus estimate of -$0.872 by -$0.068.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -$0.75.
How many shares outstanding does Guardant Health have?
Guardant Health has 122,369,220 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -$0.94 in its last earnings report, missing expectations of -$0.872. Following the earnings report the stock price went up 15.072%.
Which hedge fund is a major shareholder of Guardant Health?
Among the largest hedge funds holding Guardant Health’s share is Deerfield Management Company, LP. It holds Guardant Health’s shares valued at 16M.
---
Guardant Health Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.15 (24.07% Upside)
$38.15 (24.07% Upside)
Blogger Sentiment
Bullish
GH Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 66.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.92%
12-Months-Change
Fundamentals
Return on Equity
-3883.89%
Trailing 12-Months
Asset Growth
12.77%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.
---
GH Company Deck
---
GH Earnings Call
Q1 2024
0:00 / 0:00
---
GH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
---
GH Stock 12 Month Forecast
Average Price Target
$38.15
▲(24.07% Upside)
Technical Analysis
Best Analysts Covering GH
1 Year
1 Year Success Rate
9/10 ratings generated profit
1 Year Average Return
+31.89%
assigned a buy rating 2 months ago
Copying David Westenberg's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +31.89% per trade.
---